The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030 [COVID-19 Series]

  • Lowest Price Guaranteed From USD 4,499

  • Published
    October 2019

  • Pages
    302

  • View Count
    4673

Example Insights

Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Context 	Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-List of Needle free injectons systems Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Wide Patient population Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Types of microneedle based devices
	Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Device competitiveness analysis Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Pipeline Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Primary driving technologies Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Case Study
Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Market Sizing & Opportunity analysis Microneedles and Needle-Free Injection Systems Jet Injectors Market, 2019-2030-Market Forecast    

 

Overview

[COVID-19 SERIES] Chronic clinical conditions, such as diabetes, cardiovascular disorders, certain types of neurological disorders, and cancer, are considered to be among the leading causes of death and disability across the world. The Center for Managing Chronic Disease at the University of Michigan recently reported that over 50% of the global population is suffering from some form of chronic disease. Despite significant advances in drug / therapy development for the treatment of chronic diseases, there are several concerns related to the delivery of such therapeutics. Since most medications are developed for parenteral delivery, dosing errors and accidental needlestick injuries are some of the primary areas of concern. In fact, needle phobia is officially recognized as a medical condition by the American Psychiatric Association in its Diagnostic and Statistical Manual of Mental Disorders and is known to affect nearly 10% of the population. The Needlestick Safety and Prevention Act, which was signed into law in the US in November 2000, encouraged the development of a variety of needleless syringes / safety syringes, such as needle-free injection systems, microneedle patches and microneedle pens. A sustained focus towards self-injection has also facilitated significant advances in drug development and administration. In fact, the self-injection devices market is characterized by the presence of a myriad of advanced and innovative drug delivery solutions, such as (in alphabetical order) autoinjectors, jet injectors, large volume wearable injectors, microneedles, pen injectors, needleless syringes and prefilled syringes. In fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks / pandemics (such as the one being faced due to the novel corona virus / COVID-19), where medical centers may not be equipped to deal with large masses for delivery of therapeutic / preventive vaccines (once these get approved).

The concept of needle free drug delivery is realized using a variety of actuation mechanisms (such as spring- or gas-powered devices) that are capable of facilitating the delivery of therapeutic interventions without the use of needles. On the other hand, microneedles are extremely minute needles (of the order of a few micrometers), which are designed to deliver drugs across the dermis. It is worth highlighting that such delivery systems are primarily based on the subcutaneous / intradermal and transdermal routes. The field of needleless drug delivery continues to witness significant advances, in terms of innovation in drug / therapy administration (such as dose tracking and real-time updates) and the development of compatible drug formulations. As a result, several stakeholders in the healthcare industry have developed interest in this upcoming field, and have launched product development / commercialization initiatives in the recent past. 

Scope of the Report

The “Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities associated with the needle-free injection systems and microneedles market, over the next 10-12 years. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the needle-free injection systems market, featuring a comprehensive list of device developers and analysis based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development and commercialized), details on intellectual property portfolio, route of administration (subcutaneous, intramuscular, intradermal and others), type of load (solid and liquid), usability (disposable and reusable), actuation mechanism (spring-based, gas-powered and others), capacity of the device (in terms of volume of drug delivered) and target disease areas.   
  • An overview of the current market landscape of microneedle devices, featuring a comprehensive list of device developers and analysis based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development and commercialized), details on intellectual property portfolio, type of microneedle device (hollow, solid and dissolving), route of administration (subcutaneous, transdermal, intradermal and others), microneedle length and target disease areas.
  • A detailed product competitiveness analysis of both needle-free injection systems and microneedle devices, taking into consideration the supplier power (based on the year of establishment of developer company) and key product specifications. For needle-free injection systems, specifications, such as therapeutic area, route of administration, maximum device volume, usability, size of intellectual property portfolio, and commercial availability, were considered. For microneedles, specifications, such as therapeutic area, route of administration, length of microneedle, and size of intellectual property portfolio, were considered.
  • A list of marketed drugs / therapies and pipeline candidates that are anticipated to be developed in combination with needle free injectors and microneedles in the near future; the analysis is based on a variety of relevant parameters, such as (in alphabetical order) current status of development, dose concentration, dosing frequency, route of administration, type of dose (standard / weight dependent), expected patent expiry (relevant only for marketed drugs) and information on product sales (relevant only for marketed drugs).
  • An informed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current worth of different types of needle-free injection systems and microneedle devices.
  • Elaborate profiles of prominent product developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its product portfolio and recent developments.
  • A case study on the role of contract manufacturing organizations within the medical device industry. It includes a brief description of the various regulatory guidelines for medical devices and highlights the challenges associated with the manufacturing of such products. In addition, it features a list of contract manufacturers that claim to offer services for drug delivery devices and their geographical landscape. 

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for needle-free injection systems and microneedle devices. Based on various parameters, such as number of marketed / pipeline products, existing price of devices (for commercially available products only) and estimated annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. For needle-free injection systems, the report also features the likely distribution of the current and forecasted opportunity across [A] different types of actuation mechanisms (spring-based, gas powered and others), [B] routes of administration (subcutaneous, intramuscular and intradermal), [C] target disease indication (infectious diseases, diabetes, pain disorders and others), [D] product usability (disposable and re-usable) and [E] key geographical regions (North America, Europe, Asia and Rest of the World). Similarly, the projected future opportunity for microneedle devices has been analyzed across [A] various types of microneedle devices (hollow, solid and dissolving), [B] target disease indication (infectious diseases, osteoarthritis, pain disorders, cancer, and others), [C] type of intervention (vaccines, therapeutic agent and others), and [D] key geographical regions (North America, Europe, Asia and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Michael Schrader, CEO and Founder, Vaxess Technologies
  • Patrick Anquetil, CEO, Portal Instruments
  • Henry King, Market Intelligence and Business Development Manager, Innoture

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the needle-free injection systems and microneedle devices market and describes its evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to needle-free injection systems and microneedles, highlighting the growing demand for devices that enable painless administration of medication in the homecare setting. The chapter emphasizes the need for such devices, specifically in terms of the rising incidence and prevalence of chronic diseases. Subsequently, it provides an overview of the different types of needle free injectors and microneedles, listing their specifications and varied mechanisms of action. It also features a brief discussion on the challenges related to the R&D efforts associated with such healthcare, offering insights on anticipated future trends.

Chapter 4 provides a detailed overview of the overall landscape of needle-free injection systems that are developed / being developed for administration of various drug products. It features an in-depth analysis of the devices, based on a number of parameters, such as details on intellectual property portfolio, current status of development, route of administration (subcutaneous / intradermal / intramuscular), actuation mechanism (spring-based, gas-powered and others), type of load (liquid and solid), usability (single use and multiple use), capacity of the device (in terms of drug volume) and target disease areas. In addition, the chapter provides information on drug developer(s), highlighting year of establishment, location of headquarters and strength of employee base.

Chapter 5 provides a detailed overview of the overall landscape of microneedle devices that are developed / being developed for administration of various drugs. It features an in-depth analysis of the devices, based on a number of parameters, such as development status of various products (under development and commercialized), details on intellectual property portfolio, type of microneedle device (hollow, solid and dissolving), route of administration (subcutaneous, transdermal, intradermal and others), microneedle length and target disease areas. In addition, the chapter provides information on drug developer(s), highlighting year of establishment, location of headquarters and strength of employee base.

Chapter 6 features a product competitiveness analysis of needle-free injection systems and microneedles, based on the supplier power and product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 7 provides detailed profiles of key needle-free injection systems and microneedle device developers. Each profile presents a brief overview of the company, financial information (if available), product portfolio and recent developments.

Chapter 8 features a detailed analysis of needle-free injection systems and microneedles based on the AC (attractiveness versus competitiveness) matrix framework. It also includes a discussion on the relative market attractiveness and competitive strength of these devices. The purpose of the analysis is to enable companies to analyze their respective technical expertise, develop informed growth strategies (with respect to technical strength), and also make decisions related to acquiring new technologies or divesting the outdated ones.

Chapter 9 includes a brief case study on the role of contract manufacturing organizations that offer services for medical devices with emphasis on drug delivery devices. The chapter also features a discussion of the various challenges associated with medical device manufacturing and regulatory guidelines for medical devices. In addition, the chapter presents a region-wise mapping of the developers of the needle-free injection systems and microneedles with the availability of medical device contract manufacturers.

Chapter 10 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via needle-free injection systems in the future. The list was compiled considering various parameters, such as (in alphabetical order) current status of development, dose concentration, dosing frequency, route of administration, type of dose (standard / weight dependent), expected patent expiry (relevant only for marketed drugs) and product sales (relevant only for marketed drugs). For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via needle free injectors and microneedles in the future was estimated using the weighted average of the aforementioned parameters. 

Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via microneedle devices in the future. The list was compiled considering various parameters, such as (in alphabetical order) current status of development, dose concentration, dosing frequency, route of administration, type of dose (standard / weight dependent), expected patent expiry (relevant only for marketed drugs) and product sales (relevant only for marketed drugs). For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via needle free injectors and microneedles in the future was estimated using the weighted average of the aforementioned parameters. 

Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of needle free injectors and microneedles, till the year 2030. We have segregated the opportunity of needle-free injection systems on the basis of different types of actuation mechanisms (spring-based, gas powered and others), routes of administration (subcutaneous, intramuscular and intradermal), target disease indication (infectious diseases, diabetes, pain disorders and others), product usability (disposable and re-usable) and key geographical regions (North America, Europe, Asia and Rest of the World). Similarly, the projected future opportunity for microneedle devices has been analyzed across various types of microneedle devices (hollow, solid and dissolving), target disease indication (infectious diseases, osteoarthritis, pain disorders, cancer, and others), type of intervention (vaccines, therapeutic agent and others), and key geographical regions (North America, Europe, Asia and Rest of the World). 

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Michael Schrader (CEO and Founder, Vaxess Technologies), Patrick Anquetil (CEO, Portal Instruments) and Henry King (Market Intelligence and Business Development Manager, Innoture).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the drug delivery devices industry.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Conventional Parenteral Drug Delivery
3.2.1. Needlestick Injuries
3.2.2. Incidence and Cost Burden Related to Needlestick Injuries
 
3.3. Minimally Invasive Drug Delivery
3.3.1. Key Drivers of Minimally Invasive Drug Delivery Systems
3.3.1.1. Rising Burden of Chronic Diseases
3.3.1.2. Healthcare Cost Savings
3.3.1.3. Need for Immediate Treatment in Emergency Situations
3.3.1.4. Growing Injectable Drugs Market
3.3.1.5. Need for Improving Medication Adherence
 
3.4. Needle-Free Injection Technology
3.4.1. Key Components of Needle-Free Injection Systems
3.4.1.1. Injection Device
3.4.1.2. Nozzle
3.4.1.3. Pressure Source
3.4.2. Operating Mechanism of Needle-Free Injection Systems
3.4.3. Classification based on Type of Load
3.4.3.1. Powder-based Injectors
3.4.3.2. Liquid-based Injectors
3.4.3.3. Depot Projectile-based Injectors
 
3.4.4. Classification based on Actuation Mechanism
3.4.4.1. Spring Loaded Jet Injectors
3.4.4.2. Battery Powdered Jet Injectors
3.4.4.3. Gas Powdered Jet Injectors
3.4.4.4. Laser Powered Injectors
3.4.4.5. Lorentz Force-based Injectors
 
3.5. Drug Delivery via Microneedle Devices
3.5.1. Types of Microneedle Devices
3.5.2. Advantages of Microneedle Devices
3.5.3. Fabrication of Microneedle Devices 
3.5.4. Operating Mechanism of Microneedle Devices
 
3.6. Key Challenges related to Needle-Free Injection Systems and Microneedle Devices
3.7. Future Perspectives 
 
4. NEEDLE-FREE INJECTION SYSTEMS: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Needle-Free Injection Systems: List of Developers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Geographical Location
 
4.3. Needle-Free Injection Systems: List of Available / Under Development Devices
4.3.1. Analysis by Type of Load
4.3.2. Analysis by Route of Administration
4.3.3. Analysis by Actuation Mechanism
4.3.4. Analysis by Status of Development 
4.3.5. Analysis by Patent Availability
 
4.4. Needle-Free Injection Systems: Additional Information 
4.4.1. Analysis by Target Disease Area
4.4.2. Analysis by Device Capacity
4.4.3. Analysis by Product Usability
 
4.5. Needle-Free Injection Systems: Recent Partnerships (2015-2019)

5. MICRONEEDLE DEVICES: MARKET OVERVIEW
5.1. Chapter Overview
5.2. Microneedle Devices: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
 
5.3. Microneedle Devices: List of Available / Under Development Devices
5.3.1. Analysis by Type of Microneedle
5.3.2. Analysis by Route of Administration
5.3.3. Analysis by Microneedle Length
5.3.4. Analysis by Target Disease Area
5.3.5. Analysis by Patent Availability
 
6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis: Needle-Free Injection Systems
6.4.1. Spring-based Needle-Free Injection Systems
6.4.2. Gas-powered Needle-Free Injection Systems
6.4.3. Other Needle-Free Injection Systems
 
6.5. Product Competitiveness Analysis: Microneedle Devices
6.5.1. Hollow Microneedle Devices
6.5.2. Solid Microneedle Devices
6.5.3. Dissolving Microneedle Devices
6.5.4. Other Microneedle Devices
 
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Inovio Pharmaceuticals
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.2.1. Iject
7.2.2.2. Vitajet
7.2.2.3. Serojet
7.2.2.4. ZetaJet
7.2.2.5. Biojector 2000
7.2.2.6. Jupiter Jet
7.2.2.7. ID PEN
 
7.3. Medical International Technology
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.2.1. MED-JET MBX
7.3.2.2. MED-JET H4
7.3.2.3. MED-JET H-III
7.3.2.4. Meso-Jet
 
7.4. D'Antonio Consultants International
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.2.1. LectraJet HS
7.4.2.2. LectraJet M3 RA
7.4.2.3. LectraJet M4 RA
 
7.5. Enesi Pharma
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.2.1. ImplaVax
 
7.6. PharmaJet
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.2.1. PharmaJet Stratis
7.6.2.2. Tropis
 
7.7. Inolife Sciences
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.2.1. Inojex 30
7.7.2.2. Nanojex
 
7.8. NanoPass Technologies
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.2.1. MicronJet600
7.8.2.2. MicroPyramid
 
7.9. 3M
7.9.1. Company Overview
7.9.2. Product Portfolio
7.9.2.1. Hollow Microstructured Transdermal System
7.9.2.2. Solid Microstructured Transdermal System
 
7.10. Micropoint Technologies
7.10.1. Company Overview
7.10.2. Product Portfolio
7.10.2.1. Micropoint Patch
7.10.2.2. Hollow Microneedle Hub
 
7.12. Nemaura Pharma
7.12.1. Company Overview
7.12.2. Product Portfolio
7.12.2.1. Memspatch
7.12.2.2. Micro-Patch
7.12.2.3. Mycrolator
 
8. AC MATRIX
8.1. Chapter Overview
8.2. Overview of the AC Matrix 
8.2.1. Strong Business Units
8.2.2. Average Business Units
8.2.3. Weak Business Units
8.3. Analytical Methodology
8.4. Comparison of Needle-Free Injection Systems and Microneedle Devices 
8.5. Concluding Remarks
 
9. CASE STUDY: DRUG DELIVERY DEVICE CONTRACT MANUFACTURERS
9.1. Chapter Overview
9.2. Challenges Associated with Medical Device Manufacturing
9.3. Role of Contract Manufacturing Organizations (CMOs) in the Device Development 
9.4. Regulatory Guidelines for Medical Devices
9.5. Medical Device CMOs Offering Services for Drug Delivery Devices
9.5.1. Analysis by Year of Establishment
9.5.2. Analysis by Company size
9.5.3. Analysis by Geographical Location
9.6. Geographical Distribution of Device Developers and Contract Service Providers 
 
10. NEEDLE-FREE INJECTION SYSTEMS: LIKELY DRUG CANDIDATES
10.1. Chapter Overview
 
10.2. Marketed Drugs Candidates
10.2.1. Most Likely Candidates for Delivery via Needle-Free Injection Systems
10.1.2. Likely Candidates for Delivery via Needle-Free Injection Systems
10.2.3. Less Likely Candidates for Delivery via Needle-Free Injection Systems
10.2.4. Least Likely Candidates for Delivery via Needle-Free Injection Systems
 
10.3. Clinical Drug Candidates (Biologics)
10.3.1. Most Likely Candidates for Delivery via Needle-Free Injection Systems
10.3.2. Likely Candidates for Delivery via Needle-Free Injection Systems
10.3.3. Less Likely Candidates for Delivery via Needle-Free Injection Systems
10.3.4. Least Likely Candidates for Delivery via Needle-Free Injection Systems
 
10.4. Clinical Drug Candidates (Small Molecules)
10.4.1. Most Likely Candidates for Delivery via Needle-Free Injection Systems
10.4.2. Likely Candidates for Delivery via Needle-Free Injection Systems
10.4.3. Less Likely Candidates for Delivery via Needle-Free Injection Systems
10.4.4. Least Likely Candidates for Delivery via Needle-Free Injection Systems
 
11. MICRONEEDLE DEVICES: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs Candidates
11.2.1. Most Likely Candidates for Delivery via Microneedle Devices
11.2.2. Likely Candidates for Delivery via Microneedle Devices
11.2.3. Less Likely Candidates for Delivery via Microneedle Devices
11.2.4. Least Likely Candidates for Delivery via Microneedle Devices
 
11.3. Clinical Drug Candidates (Biologics)
11.3.1. Most Likely Candidates for Delivery via Microneedle Devices
11.3.2. Likely Candidates for Delivery via Microneedle Devices
11.3.3. Less Likely Candidates for Delivery via Microneedle Devices
11.3.4. Least Likely Candidates for Delivery via Microneedle Devices
 
11.4. Clinical Drug Candidates (Small Molecules)
11.4.1. Most Likely Candidates for Delivery via Microneedle Devices
11.4.2. Likely Candidates for Delivery via Microneedle Devices
11.4.3. Less Likely Candidates for Delivery via Microneedle Devices
11.4.4. Least Likely Candidates for Delivery via Microneedle Devices
 
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
 
12.3. Global Needle-Free Injection Systems Market, 2019-2030
12.4. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
12.5. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
12.6. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
12.7. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
12.8. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
12.8.1 Needle-Free Injection Systems Market in North America, 2019-2030
12.8.1.1. Needle-Free Injection Systems Market in North America: Distribution by Actuation Mechanism, 2019-2030
12.8.1.2. Needle-Free Injection Systems Market in North America: Distribution by Route of Administration, 2019-2030
12.8.1.3. Needle-Free Injection Systems Market in North America: Distribution by Target Disease Indication, 2019-2030
12.8.1.4. Needle-Free Injection Systems Market in North America: Distribution by Product   Usability, 2019-2030
 
12.8.2. Needle-Free Injection Systems Market in Europe, 2019-2030
12.8.2.1. Needle-Free Injection Systems Market in Europe: Distribution by Actuation Mechanism, 2019-2030
12.8.2.2. Needle-Free Injection Systems Market in Europe: Distribution by Route of Administration, 2019-2030
12.8.2.3. Needle-Free Injection Systems Market in Europe: Distribution by Target Disease Indication, 2019-2030
12.8.2.4. Needle-Free Injection Systems Market in Europe: Distribution by Product Usability, 2019-2030
 
12.8.3. Needle-Free Injection Systems Market in Asia, 2019-2030
12.8.3.1. Needle-Free Injection Systems Market in Asia: Distribution by Actuation Mechanism, 2019-2030
12.8.3.2. Needle-Free Injection Systems Market in Asia: Distribution by Route of Administration, 2019-2030
12.8.3.3. Needle-Free Injection Systems Market in Asia: Distribution by Target Disease Indication, 2019-2030
12.8.3.4. Needle-Free Injection Systems Market in Asia: Distribution by Product Usability, 2019-2030
12.8.4. Needle-Free Injection Systems Market in Rest of the World, 2019-2030
12.8.4.1. Needle-Free Injection Systems Market in Rest of the World: Distribution by Actuation Mechanism, 2019-2030
12.8.4.2. Needle-Free Injection Systems Market in Rest of the World: Distribution by Route of Administration, 2019-2030
12.8.4.3. Needle-Free Injection Systems Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
12.8.4.4. Needle-Free Injection Systems Market in Rest of the World: Distribution by Product Usability, 2019-2030
 
12.9. Global Microneedle Devices Market, 2019-2030
12.10. Global Microneedle Devices Market: Distribution by Type of Microneedle, 2019-2030
12.11. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
12.12. Global Microneedle Devices Market: Distribution by Regions, 2019-2030
 
12.12.1 Microneedle Devices Market in North America, 2019-2030
12.12.1.1. Microneedle Devices Market in North America: Distribution by Types of Microneedle Devices, 2019-2030
12.12.1.2. Microneedle Devices Market in North America: Distribution by Target Disease Indication, 2019-2030
 
12.12.2. Microneedle Devices Market in Europe, 2019-2030
12.12.2.1. Microneedle Devices Market in Europe: Distribution by Types of Microneedle Devices, 2019-2030
12.12.2.2. Microneedle Devices Market in Europe: Distribution by Target Disease Indication, 2019-2030
 
12.12.3. Microneedle Devices Market in Asia, 2019-2030
12.12.3.1. Microneedle Devices Market in Asia: Distribution by Types of Microneedle Devices, 2019-2030
12.12.3.2. Microneedle Devices Market in Asia: Distribution by Target Disease Indication, 2019-2030
 
12.12.4. Microneedle Devices Market in Rest of the World, 2019-2030
12.12.4.1. Microneedle Devices Market in Rest of the World: Distribution by Types of Microneedle Devices, 2019-2030
12.12.4.2. Microneedle Devices Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
 
13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Vaxess Technologies
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Michael Schrader, CEO and Founder 
 
13.3. Portal Instruments
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Patrick Anquetil, CEO 
 
13.3. Innoture
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Henry King, Market Intelligence and Business Development Manager
 
14. CONCLUDING REMARKS
 
15. APPENDIX 1: TABULATED DATA
 
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

Figure 3.1 Needle-Free Injection Systems: Advantages
Figure 3.2 Needle-Free Injection Systems: Key Components
Figure 3.3 Needle-Free Injection Systems: Stages of Drug Delivery
Figure 3.4 Drug Delivery via Microneedle Devices 
Figure 3.5 Microneedle Devices: Fabrication Techniques
Figure 4.1 Needle-Free Injection System Developers: Distribution by Year of Establishment
Figure 4.2 Needle-Free Injection System Developers: Distribution by Company Size and Geographical Location
Figure 4.3 Needle-Free Injection Systems: Distribution by Type of Load
Figure 4.4 Needle-Free Injection Systems: Distribution by Route of Administration
Figure 4.5 Needle-Free Injection Systems: Distribution by Actuation Mechanism
Figure 4.6 Needle-Free Injection Systems: Distribution by Status of Development
Figure 4.7 Needle-Free Injection Systems: Distribution by Patent Availability
Figure 4.8 Needle-Free Injection Systems: Distribution by Target Disease Area
Figure 4.9 Needle-Free Injection Systems: Distribution by Type of Treatment
Figure 4.10 Needle-Free Injection Systems: Distribution by Device Capacity
Figure 4.11 Needle-Free Injection Systems: Distribution by Product Usability
Figure 4.12 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2019
Figure 5.1 Microneedle Device Developers: Distribution by Year of Establishment 
Figure 5.2 Microneedle Device Developers: Distribution by Company Size and Geographical Location
Figure 5.3 Microneedle Devices: Distribution by Type of Microneedle Devices
Figure 5.4 Microneedle Devices: Distribution by Route of Administration
Figure 5.5 Microneedle Devices: Distribution by Microneedle Length
Figure 5.6 Microneedle Devices: Distribution by Target Disease Area
Figure 5.7 Microneedle Devices: Distribution by Type of Treatment 
Figure 5.8 Microneedle Devices: Distribution by Patent Availability 
Figure 6.1 Product Competitiveness Analysis: Spring-based Needle-Free Injection Systems
Figure 6.2 Product Competitiveness Analysis: Compressed Gas-based Needle-Free Injection Systems
Figure 6.3 Product Competitiveness Analysis: Other Needle-Free Injection Systems
Figure 6.4 Product Competitiveness Analysis: Hollow Microneedle Devices
Figure 6.5 Product Competitiveness Analysis: Solid Microneedle Devices
Figure 6.6 Product Competitiveness Analysis: Dissolving Microneedle Devices
Figure 6.7 Product Competitiveness Analysis: Other Microneedle Devices
Figure 7.1 Inovio Pharmaceuticals: Annual Revenues, FY 2015-FY 2019 (USD Million)
Figure 7.2  3M: Annual Revenues, FY 2016-FY 2019 (USD Billion)
Figure 8.1 AC Matrix: Comparison of Needle-Free Injection Systems and Microneedle Devices
Figure 9.1 Challenges Associated with Medical Device Manufacturing
Figure 9.2  US FDA: Review / Approval Process
Figure 9.3  Medical Device Contract Manufacturing Organizations Offering Services for Drug Delivery Devices: Distribution by Year of Establishment
Figure 9.4  Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Company Size 
Figure 9.5  Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Region-wise)
Figure 9.6  Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Country-wise) 
Figure 9.7 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment, Geographical Location and Company Size
Figure 9.8  Geographical Analysis: Needle-Free Injection System / Microneedle Device Developers and Contract Manufacturers
Figure 12.1. Global Needle-Free Injection Systems Market, 2019-2030
Figure 12.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
Figure 12.3. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
Figure 12.4. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
Figure 12.5. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
Figure 12.6. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
Figure 12.7. Needle-Free Injection Systems Market in North America, 2019-2030
Figure 12.8. Needle-Free Injection Systems Market in North America: Distribution by Actuation Mechanism, 2019-2030
Figure 12.9. Needle-Free Injection Systems Market in North America: Distribution by Route of Administration, 2019-2030
Figure 12.10. Needle-Free Injection Systems Market in North America: Distribution by Target Disease Indication, 2019-2030
Figure 12.11. Needle-Free Injection Systems Market in North America: Distribution by Product Usability, 2019-2030
Figure 12.12. Needle-Free Injection Systems Market in Europe, 2019-2030
Figure 12.13. Needle-Free Injection Systems Market in Europe: Distribution by Actuation Mechanism, 2019-2030
Figure 12.14. Needle-Free Injection Systems Market in Europe: Distribution by Route of Administration, 2019-2030
Figure 12.15. Needle-Free Injection Systems Market in Europe: Distribution by Target Disease Indication, 2019-2030
Figure 12.16. Needle-Free Injection Systems Market in Europe: Distribution by Product Usability, 2019-2030
Figure 12.17. Needle-Free Injection Systems Market in Asia, 2019-2030
Figure 12.18. Needle-Free Injection Systems Market in Asia: Distribution by Actuation Mechanism, 2019-2030
Figure 12.19. Needle-Free Injection Systems Market in Asia: Distribution by Route of Administration, 2019-2030
Figure 12.20. Needle-Free Injection Systems Market in Asia: Distribution by Target Disease Indication, 2019-2030
Figure 12.21. Needle-Free Injection Systems Market in Asia: Distribution by Product Usability, 2019-2030
Figure 12.22. Needle-Free Injection Systems Market in Rest of the World, 20219-2030
Figure 12.23. Needle-Free Injection Systems Market in Rest of the World: Distribution by Actuation Mechanism, 2019-2030
Figure 12.24. Needle-Free Injection Systems Market in Rest of the World: Distribution by Route of Administration, 2019-2030
Figure 12.25. Needle-Free Injection Systems Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
Figure 12.26. Needle-Free Injection Systems Market in Rest of the World: Distribution by Product Usability, 2019-2030
Figure 12.27. Global Microneedle Devices Market, 2019-2030
Figure 12.28. Global Microneedle Devices Market: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.29. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
Figure 12.30. Global Microneedle Devices Market: Distribution by Regions, 2019-2030
Figure 12.31. Microneedle Devices Market in North America, 2019-2030
Figure 12.32. Microneedle Devices Market in North America: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.33. Microneedle Devices Market in North America: Distribution by Target Disease Indication, 2019-2030
Figure 12.34. Microneedle Devices Market in Europe, 2019-2030
Figure 12.35. Microneedle Devices Market in Europe: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.36. Microneedle Devices Market in Europe: Distribution by Target Disease Indication, 2019-2030
Figure 12.37. Microneedle Devices Market in Asia, 20219-2030
Figure 12.38. Microneedle Devices Market in Asia: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.39. Microneedle Devices Market in Asia: Distribution by Target Disease Indication, 2019-2030
Figure 12.40. Microneedle Devices Market in Rest of the World, 20219-2030
Figure 12.41. Microneedle Devices Market in Rest of the World: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.42. Microneedle Devices Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030

List Of Tables

Table 4.1. Needle-Free Injection Systems: List of Developers
Table 4.2. Needle-Free Injection Systems: List of Available / Under Development Devices
Table 4.2. Needle-Free Injection Systems: Additional Information 
Table 4.3. Needle-Free Injection Systems: Partnerships and Collaborations, 2014-2019
Table 5.1. Microneedle Devices: List of Developers
Table 5.2. Microneedle Devices: List of Available / Under Development Devices
Table 7.1. List of Needle-Free Injection System and Microneedle Device Developers Profiled
Table 7.2. Inovio Pharmaceuticals: Company Snapshot
Table 7.3. Medical International Technology: Company Snapshot
Table 7.4. D'Antonio Consultants International: Company Snapshot
Table 7.5. Enesi Pharma: Company Snapshot
Table 7.6. PharmaJet: Company Snapshot
Table 7.7. Inolife Sciences: Company Snapshot
Table 7.8. NanoPass Technologies: Company Snapshot
Table 7.9. 3M: Company Snapshot
Table 7.10. Micropoint Technologies: Company Snapshot
Table 7.11. Nemaura Pharma: Company Snapshot
Table 9.1. List of Medical Device CMOs Offering Services for Drug Delivery Devices
Table 10.1. Marketed Molecules: Most Likely Candidates for Delivery via Needle-Free Injection Systems 
Table 10.2. Marketed Molecules: Likely Candidates for Delivery via Needle-Free Injection Systems 
Table 10.3. Marketed Molecules: Less Likely Candidates for Delivery via Needle-Free Injection Systems 
Table 10.4. Marketed Molecules: Least Likely Candidates for Delivery via Needle-Free Injection Systems 
Table 10.5. Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via   Needle-Free Injection Systems
Table 10.6. Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.7. Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.8. Clinical Drug Candidates (Biologics): Least Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.9. Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.10. Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.11. Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Needle-Free Injection Systems 
Table 10.12. Clinical Drug Candidates (Small Molecules): Least Likely Candidates for Delivery via Needle-Free Injection Systems
Table 11.1. Marketed Molecules: Most Likely Candidates for Delivery via Microneedle Devices
Table 11.2. Marketed Molecules: Likely Candidates for Delivery via Microneedle Devices 
Table 11.3. Marketed Molecules: Less Likely Candidates for Delivery via Microneedle Devices 
Table 11.4. Marketed Molecules: Least Likely Candidates for Delivery via Microneedle Devices 
Table 11.5. Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via Microneedle Devices 
Table 11.6. Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Microneedle Devices 
Table 11.7. Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Microneedle Devices 
Table 11.8. Clinical Drug Candidates (Biologics): Least Likely Candidates for Delivery via Microneedle Devices 
Table 11.9. Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Microneedle Devices 
Table 11.10. Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Microneedle Devices 
Table 11.11. Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Microneedle Devices 
Table 11.12. Clinical Drug Candidates (Small Molecules): Least Likely Candidates for Delivery via Microneedle Devices 
Table 13.1. Innoture: Company Snapshot 
Table 13.2. Portal Instruments: Company Snapshot 
Table 13.3. Vaxess Technologies: Company Snapshot 
Table 15.1. Needle-Free Injection System Developers: Distribution by Year of Establishment
Table 15.2. Needle-Free Injection Systems Developers: Distribution by Company Size and Geographical Location
Table 15.3. Needle-Free Injection Systems: Distribution by Type of Load
Table 15.4. Needle-Free Injection Systems: Distribution by Route of Administration
Table 15.5. Needle-Free Injection Systems: Distribution by Actuation Mechanism
Table 15.6. Needle-Free Injection Systems: Distribution by Status of Development
Table 15.7. Needle-Free Injection Systems: Distribution by Patent Availability
Table 15.8. Needle-Free Injection Systems: Distribution by Target Disease Area
Table 15.9. Needle-Free Injection Systems: Distribution by Type of Treatment
Table 15.10. Needle-Free Injection Systems: Distribution by Device Capacity
Table 15.11. Needle-Free Injection Systems: Distribution by Product Usability
Table 15.12. Partnerships and Collaborations: Cumulative Trend by Year, 2015-2019
Table 15.13. Microneedle Devices: Distribution by Year of Establishment
Table 15.14. Microneedle Devices: Distribution by Company Size and Geographical Location
Table 15.15. Microneedle Devices: Distribution by Type of Microneedle Devices
Table 15.16. Microneedle Devices: Distribution by Route of Administration
Table 15.17. Microneedle Devices: Distribution by Microneedle Length
Table 15.18. Microneedle Devices: Distribution by Target Disease Area
Table 15.19. Microneedle Devices: Distribution by Type of Treatment
Table 15.20. Microneedle Devices: Distribution by Patent Availability
Table 15.21. Inovio Pharmaceuticals: Annual Revenues, FY 2015-FY 2019 (USD Million)
Table 15.22. 3M: Annual Revenues, FY 2016-FY 2019 (USD Billion)
Table 15.23. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment
Table 15.24. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Company Size
Table 15.25. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Region-wise)
Table 15.26. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Country-wise)
Table 15.27. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment, Geographical Location and Company Size
Table 15.28. Global Needle-Free Injection Systems Market, 2019-2030
Table 15.29. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
Table 15.30. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
Table 15.31. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
Table 15.32. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
Table 15.33. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
Table 15.34. Needle-Free Injection Systems Market in North America, 2019-2030
Table 15.35. Needle-Free Injection Systems Market in North America: Distribution by Region
Table 15.36. Needle-Free Injection Systems Market in North America: Distribution by Actuation Mechanism, 2019-2030
Table 15.37. Needle-Free Injection Systems Market in North America: Distribution by Route of Administration, 2019-2030
Table 15.38. Needle-Free Injection Systems Market in North America: Distribution by Target Disease Indication, 2019-2030
Table 15.39. Needle-Free Injection Systems Market in North America: Distribution by Product Usability, 2019-2030
Table 15.40. Needle-Free Injection Systems Market in Europe, 2019-2030
Table 15.41. Needle-Free Injection Systems Market in Europe: Distribution by Actuation Mechanism, 2019-2030
Table 15.42. Needle-Free Injection Systems Market in Europe: Distribution by Route of Administration, 2019-2030
Table 15.43. Needle-Free Injection Systems Market in Europe: Distribution by Target Disease Indication, 2019-2030
Table 15.44. Needle-Free Injection Systems Market in Europe: Distribution by Product Usability, 2019-2030
Table 15.45. Needle-Free Injection Systems Market in Asia, 2019-2030
Table 15.46. Needle-Free Injection Systems Market in Asia: Distribution by Region
Table 15.47. Needle-Free Injection Systems Market in Asia: Distribution by Actuation Mechanism, 2019-2030
Table 15.48. Needle-Free Injection Systems Market in Asia: Distribution by Route of Administration, 2019-2030
Table 15.49. Needle-Free Injection Systems Market in Asia: Distribution by Target Disease Indication, 2019-2030
Table 15.50. Needle-Free Injection Systems Market in Asia: Distribution by Product Usability, 2019-2030
Table 15.51. Needle-Free Injection Systems Market in Rest of the World, 20219-2030
Table 15.52. Needle-Free Injection Systems Market in Rest of the World: Distribution by Actuation Mechanism, 2019-2030
Table 15.53. Needle-Free Injection Systems Market in Rest of the World: Distribution by Route of Administration, 2019-2030
Table 15.54. Needle-Free Injection Systems Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
Table 15.55. Needle-Free Injection Systems Market in Rest of the World: Distribution by Product Usability, 2019-2030
Table 15.56. Global Microneedle Devices Market, 2019-2030
Table 15.57. Global Microneedle Devices Market: Distribution by Types of Microneedle Devices, 2019-2030
Table 15.58. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
Table 15.59. Global Microneedle Devices Market: Distribution by Regions, 2023-2030
Table 15.60. Microneedle Devices Market in North America, 2023-2030
Table 15.61. Microneedle Devices Market in North America: Distribution by Region
Table 15.62. Microneedle Devices Market in North America: Distribution by Types of Microneedle Devices, 2023-2030
Table 15.63. Microneedle Devices Market in North America: Distribution by Target Disease Indication, 2023-2030
Table 15.64. Microneedle Devices Market in Europe, 2023-2030
Table 15.65. Microneedle Devices Market in Europe: Distribution by Types of Microneedle Devices, 2023-2030
Table 15.66. Microneedle Devices Market in Europe: Distribution by Target Disease Indication, 2023-2030
Table 15.67. Microneedle Devices Market in Asia, 2023-2030
Table 15.68. Microneedle Devices Market in Asia: Distribution by Region
Table 15.69. Microneedle Devices Market in Asia: Distribution by Types of Microneedle Devices, 2019-2030
Table 15.70. Microneedle Devices Market in Asia: Distribution by Target Disease Indication, 2019-2030
Table 15.71. Microneedle Devices Market in Rest of the World, 2019-2030
Table 15.72. Microneedle Devices Market in Rest of the World: Distribution by Types of Microneedle Devices, 2019-2030
Table 15.73. Microneedle Devices Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. 3M
  2. AbbVie
  3. AbGenomics
  4. Ablynx
  5. ABO Pharmaceuticals
  6. Acceleron Pharma
  7. Actavis Pharma
  8. Activa Brand Products
  9. ADC Therapeutics
  10. AdminMed
  11. Adrenomed
  12. Aduro Biotech
  13. Advaxis
  14. Aeglea BioTherapeutics
  15. Affibody
  16. Agenus
  17. AgonOx
  18. Aijex Pharma International
  19. AIM ImmunoTech
  20. Akesobio Australia
  21. AKRA DERMOJET
  22. Alder BioPharmaceuticals
  23. Alector
  24. Alexion Pharmaceuticals
  25. Alkahest
  26. Alkermes
  27. Allakos
  28. Allergan
  29. Allozyne
  30. Alnylam Pharmaceuticals
  31. AlphaCore Pharma
  32. Altor BioScience
  33. Ambrx
  34. amcure
  35. American Medical Systems
  36. AMETEK Engineered Medical Components
  37. Amgen
  38. Amicus Therapeutics
  39. Amphivena Therapeutics
  40. Amplyx Pharmaceuticals
  41. Amsino
  42. Anesiva
  43. Angiochem 
  44. Antares Pharma
  45. Antaros Medical
  46. Apex Medical Technologies
  47. Apogee Technology
  48. Aprea Therapeutics
  49. Aptevo Therapeutics
  50. argenx
  51. Argos Therapeutics
  52. ArmaGen
  53. ARMO BioSciences
  54. Aronora
  55. Asklepion Pharmaceuticals
  56. Astellas Pharma
  57. AstraZeneca
  58. Atridia 
  59. Atrion
  60. Australasian Medical & Scientific
  61. Avant Medical 
  62. AVEO Oncology
  63. Axon Neuroscience 
  64. B&A Health
  65. Basilea Pharmaceutica
  66. Baxter International
  67. Bayer HealthCare
  68. Bayhill Therapeutics
  69. Becton Dickinson
  70. BeiGene
  71. Beijing Dongfang Biotech 
  72. Beijing QS Medical Technology
  73. Berg
  74. BioArctic Neuroscience
  75. BIOCAD
  76. BIOCORP
  77. Biogen
  78. BioIntegrator 
  79. Bioject Medical Technologies
  80. BioMarin Pharmaceutical
  81. Biomedical Advanced Research and Development Authority
  82. Biomerics
  83. Bioniz Therapeutics
  84. BioNTech
  85. Bio-Path Holdings
  86. BioSerenTach
  87. Biotest
  88. Biotest Pharmaceuticals
  89. Bio-Thera Solutions
  90. BioValve Technologies
  91. Birla Institute of Technology and Science
  92. Boehringer Ingelheim
  93. Boston Pharmaceuticals
  94. Bristol-Myers Squibb
  95. Calando Pharmaceuticals
  96. CANbridge Life Sciences
  97. Cancer Advances
  98. Canon Virginia
  99. Cara Therapeutics
  100. Carclo
  101. Caretek Medical
  102. Catalyst Biosciences
  103. Celgene
  104. Celldex Therapeutics
  105. CEL-SCI
  106. Children’s Hospital of Eastern Ontario Research Institute
  107. Chimerix
  108. Chiron 
  109. CHO Pharma
  110. Chugai Pharmaceuticals
  111. Circadian Technologies
  112. Cirtec Medical
  113. Clearside Biomedical
  114. Cleveland BioLabs
  115. Conjupro Biotherapeutics
  116. Consort Medical
  117. Contract Medical International
  118. ContraFect
  119. Corium International
  120. Cour Pharmaceuticals
  121. Covestro
  122. Crossject
  123. CSL Behring
  124. CSPC ZhongQi Pharmaceutical Technology 
  125. CStone Pharmaceuticals
  126. CureTech
  127. CytoDyn 
  128. Daiichi Sankyo
  129. Sumitomo Dainippon Pharma
  130. D'Antonio Consultants International
  131. Debiotech
  132. Dekkun
  133. Delta-Fly Pharma
  134. Denderon
  135. Desitin Pharma 
  136. Diabetes Management International
  137. DiaMedica Therapeutics
  138. Diamyd Medical
  139. Doctor Pack
  140. Donatelle
  141. DSM
  142. Eastek International
  143. EG-GILERO
  144. Eisai
  145. Eli Lilly
  146. Elusys Therapeutics
  147. EMD Serono
  148. Emergent BioSolutions
  149. Emory University 
  150. Empower Clinics
  151. Endocyte
  152. Enesi Pharma
  153. EnGeneIC
  154. EpicentRx
  155. European Pharma Group
  156. Europlaz Technologies
  157. Evergreen Research
  158. F2G 
  159. Fabrico Medical
  160. Felton International
  161. Ferring Pharmaceuticals
  162. FFF Enterprises
  163. FibroGen
  164. Five Prime Therapeutics
  165. Flex
  166. FluGen
  167. Forefront Medical Technology
  168. Freudenberg Medical
  169. FUJIFILM Pharmaceuticals
  170. Galaxy Biotech
  171. Galena Biopharma
  172. Genentech
  173. GENERON
  174. GeneScience Pharmaceuticals
  175. Genexine
  176. Genzyme
  177. Georgia Institute of Technology
  178. GeoVax
  179. Gerresheimer
  180. Gilead Sciences
  181. GlaxoSmithKline
  182. Glenmark Pharmaceuticals
  183. Glide Technologies
  184. Gliknik
  185. Guangzhou Cellprotek Pharmaceutical
  186. GW Plastics
  187. H&T Presspart
  188. HAL Allergy
  189. Halozyme Therapeutics
  190. Hanmi Pharmaceutical
  191. Haywood Vocational Opportunities
  192. Hoffmann-La Roche
  193. Huabo Biopharm
  194. IEC Electronics
  195. ImClone Systems
  196. Immatics Biotechnologies
  197. Immune Response BioPharma 
  198. ImmunGene
  199. Immunocore
  200. ImmunoFrontier
  201. ImmunoGen
  202. Immunomedics
  203. Immunotope
  204. Immunovaccine
  205. ImmuPatch
  206. Implicit Bioscience
  207. Incuron
  208. Incyte
  209. INCYTO
  210. Injex
  211. Innate Pharma
  212. Innoture Medical Technology
  213. Innovent Biologics
  214. Inolife Sciences
  215. Inovio Pharmaceuticals
  216. Integer
  217. Interplex
  218. iNtRON Biotechnology
  219. Inzign
  220. IO Biotech
  221. Ionis Pharmaceuticals
  222. Ipsen
  223. ISU ABXIS
  224. Jabil
  225. Janssen Pharmaceuticals
  226. Jerini
  227. JHL Biotech
  228. Jiangsu Hengrui Medicine
  229. Jiangsu T-Mab Biopharma 
  230. Johnson & Johnson
  231. Jounce Therapeutics
  232. Julphar
  233. KaloBios Pharmaceuticals
  234. KeyBioscience
  235. Kiniska Pharmaceuticals
  236. Kissei Pharmaceutical
  237. Kura Oncology
  238. Kyowa Hakko Kirin
  239. Lenis Medicals
  240. LEO Pharma
  241. Levicept
  242. Life Science Pharmaceuticals
  243. LTS
  244. Lundbeck
  245. M&M Qualtech
  246. MabVax Therapeutics
  247. Mack Molding
  248. MacroGenics
  249. Mada Medical Products
  250. Marathon Pharmaceuticals
  251. McGowan Institute for Regenerative Medicine
  252. McKesson and Moore Medical
  253. Medical International Technology
  254. MedImmune
  255. MedRx
  256. Menarini Group
  257. Merck
  258. Mereo BioPharma
  259. Meridian Medical Technologies
  260. Merrimack Pharmaceuticals
  261. Mersana Therapeutics
  262. Merus
  263. Merz Pharma
  264. Microdermics
  265. Micron Biomedical
  266. Micropoint Technologies
  267. Midwest Interventional Systems
  268. Mika Medical
  269. Millennium Pharmaceuticals
  270. MiNA Therapeutics
  271. miRagen Therapeutics
  272. Mitsubishi Tanabe Pharma
  273. Moderna Therapeutics
  274. Modulus
  275. Molecular Partners
  276. Molecular Templates
  277. MolMed
  278. MorphoSys
  279. Morphotek
  280. Movi SpA
  281. Mundipharma
  282. National Association of Convenience Stores
  283. Namaste Technologies
  284. NanoPass Technologies
  285. NantBioScience
  286. Nanyang Technological University
  287. Natech Plastics
  288. National University of Singapore
  289. Naurex
  290. Navidea Biopharmaceuticals
  291. Nemaura Pharma
  292. Nemera
  293. Neogenix Oncology
  294. Neon Therapeutics
  295. Neotech Medical
  296. Nexeon MedSystems
  297. Nordic Bioscience 
  298. Northern Biologics
  299. Novartis
  300. NovInject
  301. Novo Nordisk
  302. OBI Pharma
  303. Occam Design
  304. Octapharma
  305. Omeros
  306. Oncology Venture
  307. OncoMed Pharmaceuticals
  308. OncoPep
  309. Oncopeptides
  310. Oncternal Therapeutics
  311. Oncurious 
  312. Optimer Biotechnology
  313. OSE Immunotherapeutics
  314. Otsuka Pharmaceutical
  315. P3 Medical
  316. Paion UK
  317. Paramit
  318. PATH
  319. Penjet
  320. Peridot
  321. Pfizer
  322. Pharma Tech
  323. PharmaJet
  324. PharmaMar
  325. PhaseBio Pharmaceuticals
  326. Phillips-Medisize
  327. Philogen
  328. Phosplatin Therapeutics
  329. Picofluidics
  330. Pierre Fabre
  331. Pique Therapeutics
  332. Plastikon
  333. Plexus
  334. Polaris Group
  335. Polyphor
  336. Polyzen
  337. Portal Instruments
  338. Precision Engineered Products
  339. Precision MicroFab
  340. Preco
  341. PrECOG
  342. Premier Distributing
  343. Prescient Therapeutics
  344. Prestige BioPharma
  345. Pro-Dex
  346. Promedior
  347. Prometheus Laboratories
  348. Protalix Biotherapeutics
  349. Proven Process Medical Devices
  350. Providence Enterprise
  351. Public Health England
  352. Pulse NeedleFree Systems
  353. Quality Tech Services
  354. Quest PharmaTech 
  355. Quintessence Biosciences
  356. Radius Health
  357. Recro Pharma
  358. Regeneron Pharmaceuticals
  359. REMD Biotherapeutics
  360. Resolve Therapeutics
  361. rEVO Biologics
  362. Rhythm Pharmaceuticals
  363. Riverside Medical Packaging
  364. Röchling Medical
  365. Samsung Bioepis
  366. SanaVita Medical
  367. Sanmina
  368. Sanofi
  369. Santarus 
  370. Sanzyme
  371. Savient Pharmaceuticals
  372. scPharmaceuticals
  373. Seattle Genetics
  374. Selecta Biosciences
  375. Selexys Pharmaceuticals
  376. Sementis
  377. Seoul National University
  378. Serina Therapeutics
  379. Serum Institute of India
  380. Shire
  381. SHL Group
  382. Shreya Life Sciences
  383. SkinJect
  384. SMC
  385. Sovrin Plastics
  386. Stealth BioTherapeutics 
  387. Stellartech Research
  388. SteriPack
  389. Stevanato Group
  390. Sunovion Pharmaceuticals
  391. Switchback Medical
  392. SymBio Pharmaceuticals
  393. Symphogen 
  394. Synermore Biologics
  395. Syntimmune
  396. Syros Pharmaceuticals
  397. TaiMed Biologics
  398. Taiwan Liposome Company
  399. Takeda Pharmaceutical
  400. Tanvex BioPharma
  401. Tarveda Therapeutics
  402. Teva Pharmaceutical
  403. TG Therapeutics
  404. The National Medical Products
  405. TheraJect
  406. The University of Iowa
  407. Tolero Pharmaceuticals
  408. TRACON Pharmaceuticals
  409. Translational Sciences
  410. Trelleborg Sealing Solutions
  411. Trend Technologies
  412. TRICOR Systems
  413. TRITECH BIOMED INTERNATIONAL
  414. Turnstone Biologics
  415. UCB
  416. United BioPharma
  417. University of Oxford
  418. University of South Australia
  419. Vaccibody
  420. Vaccinex
  421. Valeritas
  422. Valtronic
  423. VascuTech Medical
  424. vasopharm BIOTECH 
  425. Vaupell
  426. Vaxxas
  427. Vaxess Technologies
  428. ViiV Healthcare
  429. Visterra
  430. ViVO Smart Medical Devices
  431. Vivozon
  432. Vizient
  433. Walter Reed Army Institute of Research
  434. West Pharmaceutical Services
  435. Westmed Medical Group
  436. Wockhardt
  437. World Health Organization
  438. XBiotech
  439. Xencor
  440. Xi'an Xintong Pharmaceutical Research
  441. XOMA
  442. Zafgen
  443. Zenius
  444. Zogenix
  445. Zosano Pharma

Segmentation

The financial opportunity within the needle-free injection systems and microneedle devices market has been analyzed across the following segments:

  • Actuation Mechanism (Needle-Free Injection Systems only)
    • Spring-based
    • Gas powered
    • Others 
  • Product Usability (Needle-Free Injection Systems only)
    • Disposable
    • Re-usable 
  • Route of Administration (Needle-Free Injection Systems only)
    • Subcutaneous
    • Intramuscular
    • Intradermal
  • Types of Microneedle Devices (Microneedle Devices only)
    • Hollow
    • Solid
    • Dissolving 
  • Type of Intervention (Microneedle Devices only)
    • Vaccine
    • Therapeutic Agent
    • Others
  • Target Disease Indication
    • Infectious Diseases
    • Osteoarthritis
    • Pain Disorders
    • Cancer
    • Others
  • Key geographical regions 
    • North America
    • Europe
    • Asia
    • Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com